372 related articles for article (PubMed ID: 18520289)
21. Alendronate treatment in children with osteogenesis imperfecta.
Akcay T; Turan S; Guran T; Bereket A
Indian Pediatr; 2008 Feb; 45(2):105-9. PubMed ID: 18310788
[TBL] [Abstract][Full Text] [Related]
22. Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta.
Rauch F; Cornibert S; Cheung M; Glorieux FH
Bone; 2007 Apr; 40(4):821-7. PubMed ID: 17223617
[TBL] [Abstract][Full Text] [Related]
23. Pamidronate affects the mandibular cortex of children with osteogenesis imperfecta.
Apolinário AC; Figueiredo PT; Guimarães AT; Acevedo AC; Castro LC; Paula AP; Paula LM; Melo NS; Leite AF
J Dent Res; 2015 Mar; 94(3 Suppl):95S-102S. PubMed ID: 25608973
[TBL] [Abstract][Full Text] [Related]
24. Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome.
Munns CF; Rauch F; Travers R; Glorieux FH
J Bone Miner Res; 2005 Jul; 20(7):1235-43. PubMed ID: 15940378
[TBL] [Abstract][Full Text] [Related]
25. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
Glorieux FH; Bishop NJ; Plotkin H; Chabot G; Lanoue G; Travers R
N Engl J Med; 1998 Oct; 339(14):947-52. PubMed ID: 9753709
[TBL] [Abstract][Full Text] [Related]
26. Intravenous pamidronate therapy in Taiwanese patients with osteogenesis imperfecta.
Lin HY; Lin SP; Chuang CK; Chen MR; Chang CY
Pediatr Neonatol; 2008 Oct; 49(5):161-5. PubMed ID: 19133566
[TBL] [Abstract][Full Text] [Related]
27. Zoledronic acid treatment in children with osteogenesis imperfecta.
Vuorimies I; Toiviainen-Salo S; Hero M; Mäkitie O
Horm Res Paediatr; 2011; 75(5):346-53. PubMed ID: 21293106
[TBL] [Abstract][Full Text] [Related]
28. Pamidronate treatment of children with moderate-to-severe osteogenesis imperfecta: a note of caution.
Alharbi M; Pinto G; Finidori G; Souberbielle JC; Guillou F; Gaubicher S; Le Merrer M; Polak M
Horm Res; 2009 Jan; 71(1):38-44. PubMed ID: 19039235
[TBL] [Abstract][Full Text] [Related]
29. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age.
Plotkin H; Rauch F; Bishop NJ; Montpetit K; Ruck-Gibis J; Travers R; Glorieux FH
J Clin Endocrinol Metab; 2000 May; 85(5):1846-50. PubMed ID: 10843163
[TBL] [Abstract][Full Text] [Related]
30. Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate.
Lindahl K; Kindmark A; Rubin CJ; Malmgren B; Grigelioniene G; Söderhäll S; Ljunggren Ö; Åström E
Bone; 2016 Jun; 87():11-8. PubMed ID: 26957348
[TBL] [Abstract][Full Text] [Related]
31. Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy.
Arikoski P; Silverwood B; Tillmann V; Bishop NJ
Bone; 2004 Mar; 34(3):539-46. PubMed ID: 15003801
[TBL] [Abstract][Full Text] [Related]
32. Benefits of pamidronate in children with osteogenesis imperfecta: an open prospective study.
Forin V; Arabi A; Guigonis V; Filipe G; Bensman A; Roux C
Joint Bone Spine; 2005 Jul; 72(4):313-8. PubMed ID: 16038843
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta.
Barros ER; Saraiva GL; de Oliveira TP; Lazaretti-Castro M
J Pediatr Endocrinol Metab; 2012; 25(5-6):485-91. PubMed ID: 22876543
[TBL] [Abstract][Full Text] [Related]
34. Short-term efficacy of monthly pamidronate infusion in patients with osteogenesis imperfecta.
Choi JH; Shin YL; Yoo HW
J Korean Med Sci; 2007 Apr; 22(2):209-12. PubMed ID: 17449925
[TBL] [Abstract][Full Text] [Related]
35. Bisphosphonate therapy for osteogenesis imperfecta.
Dwan K; Phillipi CA; Steiner RD; Basel D
Cochrane Database Syst Rev; 2014 Jul; (7):CD005088. PubMed ID: 25054949
[TBL] [Abstract][Full Text] [Related]
36. Two doses of pamidronate in infants with osteogenesis imperfecta.
Senthilnathan S; Walker E; Bishop NJ
Arch Dis Child; 2008 May; 93(5):398-400. PubMed ID: 18089634
[TBL] [Abstract][Full Text] [Related]
37. Effect of cyclical intravenous pamidronate therapy in children with osteogenesis imperfecta. Open-label study in seven patients.
Giraud F; Meunier PJ
Joint Bone Spine; 2002 Oct; 69(5):486-90. PubMed ID: 12477233
[TBL] [Abstract][Full Text] [Related]
38. Long-term follow-up in osteogenesis imperfecta type VI.
Trejo P; Palomo T; Montpetit K; Fassier F; Sato A; Glorieux FH; Rauch F
Osteoporos Int; 2017 Oct; 28(10):2975-2983. PubMed ID: 28689307
[TBL] [Abstract][Full Text] [Related]
39. Intravenous pamidronate in osteogenesis imperfecta type VII.
Cheung MS; Glorieux FH; Rauch F
Calcif Tissue Int; 2009 Mar; 84(3):203-9. PubMed ID: 19137231
[TBL] [Abstract][Full Text] [Related]
40. Pamidronate treatment of osteogenesis imperfecta--lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response.
Zacharin M; Bateman J
J Pediatr Endocrinol Metab; 2002 Feb; 15(2):163-74. PubMed ID: 11874181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
